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ABSTRACT
There is currently no pharmacotherapy for obstructive
sleep apnoea (OSA) but there is no principled a priori
reason why there should not be one. This review identi-
ﬁes a rational decision-making strategy with the neces-
sary logical underpinnings that any reasonable
approach would be expected to navigate to develop a
viable pharmacotherapy for OSA. The process ﬁrst
involves phenotyping an individual to quantify and
characterize the critical predisposing factor(s) to their
OSA pathogenesis and identify, a priori, if the patient is
likely to beneﬁt from a pharmacotherapy that targets
those factors. We then identify rational strategies to
manipulate those critical predisposing factor(s), and the
barriers that have to be overcome for success of any
OSA pharmacotherapy. A new analysis then identiﬁes
candidate drug targets to manipulate the upper airway
motor circuitry for OSA pharmacotherapy. The ﬁrst
conclusion is that there are two general pharmacologi-
cal approaches for OSA treatment that are of the most
potential beneﬁt and are practically realistic, one being
fairly intuitive but the second perhaps less so. The sec-
ond conclusion is that after identifying the critical phys-
iological obstacles to OSA pharmacotherapy, there are
current therapeutic targets of high interest for future
development. The ﬁnal analysis provides a tabulated
resource of ‘druggable’ targets that are relatively
restricted to the circuitry controlling the upper airway
musculature, with these candidate targets being of high
priority for screening and further study. We also
emphasize that a pharmacotherapy may not cure OSA
per se, but may still be a useful adjunct to improve the
effectiveness of, and adherence to, other treatment
mainstays.
Key words: neurobiology, obstructive sleep apnoea, pheno-
type, sleep, translational medical research.
Abbreviations: 5-HT2c, 5-hydroxytryptamine 2c; AHI, apnoea–
hypopnoea index; CFTR/MRP, Cystic ﬁbrosis transmembrane
conductance regulator/Multidrug resistance-associated protein;
CPAP, continuous positive airway pressure; FDA, Food and Drug
Administration; GABA: γ-aminobutyric acid; GPCR, G-protein
coupled receptor; HMN, hypoglossal motor nucleus; ISH, in situ
hybridization; Kir2.4, inward-rectifying potassium 2.4; nCPAP,
nasal CPAP; NMDA3B, N-methyl-D-aspartate receptor 3B; OSA,
obstructive sleep apnoea; PaCO2, partial pressure of carbon
dioxide; PIP3, phosphatidylinositol 3,4,5 trisphosphate; PRE-
HMN, premotor HMN; REM, rapid eye movement.
INTRODUCTION
Strategic decisions are long-term complex choices that
affect the subsequent course of action for a large entity
like a business or a ﬁeld. Strategic decision-making in
business can result in a corporation breaking new
ground and becoming a market leader. Strategic
decision-making in physiology and medicine can lead
to breaking new ground for a medical problem in a dis-
tinct patient population, leading to new, or better,
treatment options or outcomes.
Obstructive sleep apnoea (OSA) is a common and
serious breathing problem with signiﬁcant clinical,
social and economic consequences.1–3 There is cur-
rently no pharmacotherapy for OSA. However, there is
no principled a priori reason why there should not be
one—unless the biology simply cannot support it
because of the complexity and individuality of OSA
pathogenesis. The main thrust of this review is to iden-
tify a decision-making strategy with the necessary logi-
cal underpinnings that any reasonable approach would
be expected to navigate in order to develop a viable
pharmacotherapy for OSA—while also avoiding the
identiﬁable and sometimes predictable pitfalls. We
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then identify rational strategies to manipulate those
critical predisposing factor(s), and the typically over-
looked barriers that have to be overcome for success of
any OSA pharmacotherapy. This review also provides a
new analysis that identiﬁes candidate drug targets to
manipulate the upper airway motor circuitry for OSA
pharmacotherapy. This analysis will be a valuable
resource for the ﬁeld moving forward.
It is also necessary at the outset to state upfront that
this review does not take the stance that potential phar-
macotherapy for OSA is automatically an alternate for
mainstays of treatment such as nasal continuous positive
airway pressure (nCPAP). Although treatment of OSA
with nCPAP is effective when the prescribed pressures
are tolerated and present throughout the night, subopti-
mal adherence and effectiveness are common.4,5 In this
context, a pharmacotherapy for OSA may be viewed in
the ﬁrst instance as a useful adjunct to help improve
upper airway stability and/or stabilize breathing. Such an
intervention may, therefore, improve the effectiveness of,
and adherence to, other treatment mainstays, for exam-
ple, by reducing the absolute pressure required for effec-
tive nCPAP therapy or the amount of jaw repositioning
for effective oral appliance therapy. We also recognize
that other strategies to increase tongue muscle tone via
non-pharmacological means, for example, surgically
implanted upper airway stimulation devices,6–8 may also
prove effective for the treatment of OSA.
PHENOTYPING OSA PATIENTS IS
CRITICAL TO TARGETED THERAPY
Regardless of OSA severity, all OSA patients present with
a trio of characteristic features: (i) repeated episodes of
upper airway obstruction that occur only during sleep,
accompanied by (ii) repeated episodes of obstruction-
related asphyxia, plus (iii) sleep disturbance. The sim-
plicity and reproducibility of these presenting features in
all patients, however, masks the complexity and individ-
uality of the underlying physiology in each patient that
initiates the repetitive cycles of OSA in the ﬁrst place.
The ﬁrst key point to be made here is that varying combi-
nations of predisposing factors contribute to the patho-
genesis of OSA within a given individual: that is, different
individuals have OSA for different reasons and these rea-
sons (traits) can now be identiﬁed and quantiﬁed.9–14
The main predisposing factors to the manifestation
of OSA include: (i) an anatomical predisposition to
upper airway obstructions; (ii) diminished effectiveness
of the upper airway neural compensatory mechanisms
that are either already present to prevent an obstruc-
tion or recruited to reopen the airspace; (iii) enhanced
loop gain that predisposes to respiratory control insta-
bility and sleep apnoea; (iv) arousals from sleep that
also destabilize breathing and can precipitate further
sleep apnoea after an initial event has occurred;
(v) decreased functional residual capacity that occurs
in sleep, and is exacerbated by obesity, that increases
upper airway collapsibility; and/or (vi) rostral ﬂuid
shifts when adopting the supine position that may also
increase upper airway collapsibility.9–13,15
The second key point related to these physiological
factors that can initiate and sustain OSA is that any one
(or combination) of them can be critical to pathogene-
sis within and between patients. More speciﬁcally,
while the presence of one or more of these factors may
be the tipping point for OSA pathogenesis in a particu-
lar patient, the combination of critical factors may be
quite different for another. For example, Patients A and
B may have similar OSA severities as judged by their
respective apnoea–hypopnoea indices (AHIs). How-
ever, the key elements to OSA pathogenesis in Patient
A may be an anatomical predisposition to upper airway
obstructions plus diminished pharyngeal dilator muscle
compensatory reﬂexes that are insufﬁcient to reopen
the airspace once closed. In contrast, the key predis-
posing factors causing OSA in Patient B may be
enhanced loop gain and heightened arousal responses,
both of which destabilize breathing and can precipitate
recurrent apnoeas.9–13 Treatment with nCPAP would be
beneﬁcial to both patients but if they are non-compli-
ant, what is the alternative? The principle that arises
from this discussion is that in failed or restricted
nCPAP users, personalized therapy targeting the pri-
mary factors(s) contributing to OSA pathogenesis
would beneﬁt those individual patients. Importantly,
however, the choice of personalized treatment other
than nCPAP for Patient A would be different than for
Patient B. Patient A would likely beneﬁt the most from
oral appliance therapy, whereas Patient B may be bet-
ter served by a pharmacological intervention to lower
loop gain and arousal threshold.10,16,17 Also importantly,
swapping therapy between patients would be particu-
larly ineffective (e.g. Patient A instead receiving a phar-
macological intervention to lower loop gain and
arousal threshold and Patient B receiving oral appli-
ance therapy), as the interventions would not target the
primary causative factor in those individuals.
The outcome of this initial discussion is that any clini-
cal trial of any potential therapeutic option in unselected
patients with OSA (other than with nCPAP) will likely
show some responders, partial responders and non-
responders within the cohort. This mix of outcomes is
entirely predictable because different individuals have
OSA for different reasons. Even if the pharmacotherapy
is 100% effective in modulating the mechanism it is
designed for, the response will be successful only in a
subset of patients because only in those will the targeted
mechanism be relevant to their OSA. It is possible (even
likely), therefore, that some potentially useful therapeutic
strategies may have been prematurely dismissed because
the intervention was tested in a group of unselected OSA
patients, many of whom would not be expected to
respond given the differing factors that are responsible
for their particular OSA phenotype.
It is for these reasons that here we identify the ﬁrst
strategic requirement before moving forward to develop-
ing a potential pharmacotherapy for OSA: First, pheno-
type an individual OSA patient to characterize and
quantify their critical predisposing factors and identify, a
priori, if the patient is likely to beneﬁt from a pharmaco-
therapy that targets their major predisposing factor(s).
Once a patient has been phenotyped and the critical fac-
tors predisposing to their OSA have been identiﬁed, the
second necessary key strategic decision is: Identify cur-
rent rational and viable pharmacologic targets(s) and the
barriers to be overcome for their success. Finally, we
© 2017 The Authors
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identify and discuss the third strategic decision: Identify
the next generation of targets and approaches that may be
brought to bear on this problem. The physiological bases
for these three key strategic decisions of potential thera-
peutic value are discussed in the following sections.
PHENOTYPING PATIENTS WITH OSA
AND POTENTIAL PHARMACOLOGICAL
TARGETS ARISING
Here, we identify a procedure for measuring and mod-
elling the phenotypic traits causing OSA. While this
procedure is not the only way of quantifying the phe-
notypic traits, it is detailed here for several reasons. It
will serve as a platform for deﬁning each of the pheno-
typic traits. It will also demonstrate how the different
phenotypic traits interact to produce OSA and thus will
also serve as a review of the multifactorial nature of
this disorder. Finally, it will also provide the framework
for categorizing different potential pharmacological
approaches to treating OSA. It is also noted that while
the techniques presented here may currently be too
costly for routine clinical sleep studies, less expensive
methods for phenotyping are being developed and
tested.18–21 These less expensive phenotyping methods
are based on the same principles presented here but
differ in subtle ways, making the derived parameters
accessible from the clinical polysomnogram.
The main aim of this section of the review is to empha-
size that, in the opinion of these authors, there are two
general pharmacological approaches to OSA treatment
that are of the most potential beneﬁt and practically real-
istic. The ﬁrst approach is to improve the anatomy
and/or pharyngeal dilator muscle activation. This
approach is fairly intuitive but anatomical approaches
using surgery and mechanical devices are not universally
effective or tolerated, and the pharmacological agents
and targets to achieve this goal have remained elusive
(although there are rational and newly identiﬁed strate-
gic directions that are identiﬁed in later sections). The
second approach to the pharmacological treatment of
OSA is perhaps less intuitive and appreciated, but may
be more practically realistic in the short term given cur-
rently available pharmacological agents. This second
approach is to reduce the ventilatory control sensitivity
and/or raise the arousal threshold. It is the aim of this
review to summarize the logical and physiological frame-
work for these approaches in OSA patients.
The components of the phenotype model
The phenotypic traits associated with OSA
(as described here) can be quantiﬁed as four ‘ventila-
tion levels’.11 As outlined below and illustrated sche-
matically in Figure 1, these four ventilation levels can
be measured by adjusting nCPAP during sleep and
then measuring the associated changes in ventilation.
Following the description of each of the ventilation
levels and how they relate to the phenotypic traits, a
physiological model of breathing will be described. It is
this model that will make clear what the potential ther-
apeutic targets are for OSA.
Veupnoea
The ﬁrst ventilation level determined in the phenotyp-
ing procedure is the eupnoeic ventilation during sleep
when the airway is open (abbreviated Veupnoea). This
value is the patient’s ventilatory demand or ventilatory
requirement during sleep, based on their metabolic
rate and dead space ventilation. It is obtained from
measuring the minute ventilation on optimum nCPAP.
In the simulated data in Figure 1, the Veupnoea is 5 L/
min. Note that, while the Veupnoea as well as the other
phenotypic components presented in Figure 1 are pre-
sented as constant values, in reality these variables vary
over the course of the night in an individual, for exam-
ple, by  0.5 L/min.11
Passive V0
Next, the nCPAP is abruptly dropped from an optimum
level to 0 cm H2O for ﬁve breaths. This intervention is
repeated several times. The resulting ventilation at
0 cm H2O is the ventilation that the patient can achieve
through a passive airway, and it is a measure of their
passive airway collapsibility. This designation is
because the stiffness of the upper airway is affected by
pharyngeal muscle activation, and nCPAP reduces this
activation. Furthermore, the muscles remain relatively
inactive, or ‘passive’, for the few breaths after nCPAP is
abruptly dropped;22 hence the term ‘Passive V0’ deﬁned
as the ventilation achieved through this passive upper
airway at 0 cm H2O. In the accompanying example, the
Passive V0 is 0.5 L/min. This low level of Passive V0
indicates a signiﬁcantly collapsible airway.
Varousal
After several Passive V0 measurements are made,
nCPAP is slowly reduced by 1 cm H2O for every
1–2 min. During this slow nCPAP reduction, the airway
becomes progressively narrower, leading to gradually
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Figure 1 Schematic drawing of the continuous positive airway
pressure (CPAP) manipulations used to measure the phenotypic
traits. Active V0, ventilation off CPAP (CPAP of 0 cm H2O) when
the upper airway muscles are active; CPAPmin, minimum tolera-
ble CPAP, which is the minimum CPAP that an individual can tol-
erate before having respiratory effort-related arousals; Passive
V0, ventilation off CPAP (i.e. at a CPAP of 0 cm H2O) when the
upper airway muscles are passive; Varousal, the ventilation at
which arousal occurs or the ‘minimum tolerable ventilation’;
Veupnoea, eupnoeic ventilation on optimum CPAP, which is a
measure of the patient’s ventilatory requirements under resting
conditions when the airway is completely open.
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reduced ventilation and increased PaCO2 (partial pres-
sure of carbon dioxide). The increased PaCO2 and ven-
tilatory drive eventually leads to an arousal from sleep.
Provided that the ventilation was reduced slowly
enough, the ventilation prior to arousal is a measure of
how much ventilation can be decreased before the
patient arouses from sleep, that is Varousal is the
patient’s ‘minimum tolerable ventilation’ during sleep.
The Varousal is inﬂuenced by two factors; the arousal
threshold and the sensitivity of the ventilatory control
system. The lower the arousal threshold, or the more
sensitive the ventilatory control system, the higher the
Varousal will be, thus indicating that the patient can only
tolerate a small reduction in ventilation before waking
up. Therefore, Varousal is a composite measurement of
both arousal threshold and ventilatory control sensitiv-
ity. In Figure 1, Varousal is 3.5 L/min, which is 1.5 L/min
below Veupnoea and represents a relatively low Varousal
compared with Veupnoea.
Active V0
The fourth phenotypic trait is the amount of ventilation
the patient can achieve through an activated pharyn-
geal airway. This value is termed the ‘Active V0’, or the
ventilation achieved at 0 cm H2O when the pharyngeal
muscles are activated as much as possible without
arousing from sleep. Active V0 is measured as follows.
After the measurement of Varousal (described above),
the nCPAP level is maintained at the same low level
(termed the ‘CPAPmin’) for 1–3 min to see if arousal
occurs. If not, then the nCPAP is decreased to 0 cm
H2O for ﬁve breaths to measure how much ventilation
can be achieved when ventilatory drive to the upper
airway is maximal. The difference between Active V0
and Passive V0 is an indicator of the ability of the
patient’s upper airway to compensate (i.e. to reopen) by
itself based on reﬂex compensatory mechanisms
and/or pharmacologically driven increased pharyngeal
muscle tone. The simulated patient depicted in
Figure 1 has mild compensatory ability, as indicated by
the Active V0 being only 1 L/min above Passive V0.
Manipulating the components of the
phenotype model
Measuring the phenotypic traits is only the ﬁrst step;
the second step is to determine which of the traits
should be treated. To this end, the four ventilation
levels are plotted (Fig. 2), and this representation of the
phenotype model illustrates how the phenotypic traits
interact to produce OSA. Figure 2 can be ‘read’ as fol-
lows. Starting at the top, Veupnoea is the minute ventila-
tion measured on optimum nCPAP. If nCPAPs were to
be turned off abruptly (i.e. simulating sleep onset),
then ventilation would decrease to Passive V0. Breath-
ing at Passive V0 causes the PaCO2 and ventilatory
drive to increase. The increase in ventilatory drive sti-
mulates the upper airway muscles and increases venti-
lation according to the reﬂex upper airway
compensatory effectiveness of the particular patient. If
the compensatory ventilation, or Active V0, cannot be
brought above the minimum tolerable ventilation
(i.e. Varousal), then the patient arouses from sleep,
hyperventilates temporarily until sleep resumes and
the cycle repeats. This cyclical pattern of breathing
deﬁnes their OSA. If, however, the Active V0 can be
brought above Varousal, then stable breathing occurs,
that is there is no OSA. Therefore, to eliminate OSA,
the maximum achievable ventilation during sleep
(Active V0) of a patient must be brought above the
minimum tolerable ventilation (Varousal). The difference
between Varousal and Active V0 is the ‘gap’ that must be
overcome to prevent OSA.
Having provided measured estimates of the pheno-
typic traits in an individual and placed them on the
model, it is then possible to simulate treatment and
determine which therapy would be the most appropri-
ate based on these measures (Fig. 3). For example, pre-
vious studies have shown that acetazolamide reduces
the sensitivity of the ventilatory control system, which
would lower Varousal, that is the patient can tolerate
lower ventilation during sleep.23 In addition, the hyp-
notic eszopiclone raises the arousal threshold,24 which
also has the effect of lowering Varousal. These two treat-
ments can be simulated by moving Varousal down by
some amount based on the effect size of these treat-
ments on Varousal (see the downward arrow in Fig. 3).
Therefore, it is important to know the effect size of a
particular treatment on a particular trait in order to
predict responsiveness to that treatment within an indi-
vidual; for example, ‘Patient B’ as introduced in the
Phenotyping OSA patients is critical to targeted therapy
Section.
To simulate an anatomical intervention, such as oral
appliance therapy or a pharmacotherapy that stimu-
lates the pharyngeal muscles, the Passive V0 and Active
0
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Figure 2 The phenotype model showing the relationship
between the four ventilation variables and the ‘Gap’ that must
be overcome to achieve stable breathing. Active V0, ventilation
off continuous positive airway pressure (CPAP) (CPAP of 0 cm
H2O) when the upper airway muscles are active; Passive V0, ven-
tilation off CPAP (i.e. at a CPAP of 0 cm H2O) when the upper air-
way muscles are passive; Varousal, the ventilation at which
arousal occurs, or the ‘minimum tolerable ventilation’; Veupnoea,
eupnoeic ventilation on optimum CPAP, which is a measure of
the patient’s ventilatory requirements under resting conditions
when the airway is completely open.
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V0 can be increased by some amount, again based on
experimental data. The third step is to calculate the
‘new gap’, which is calculated as follows: New gap =
Simulated Varousal − Simulated Active V0. If the new
gap is positive, then the patient is predicted to still
have OSA on the treatment in question. Alternatively, if
the new gap is negative, then it is predicted that OSA
will be attenuated or resolved with the treatment. In
theory, the more negative the new gap, the greater the
likelihood of success with a particular treatment. The
more positive the new gap, however, the less likelihood
that the treatment will be clinically effective.
This modelling approach identiﬁes the two general
strategies that can be undertaken to treat OSA. The ﬁrst
strategy, which is the most obvious, involves treatments
that increase the size of the pharynx using devices or
surgeries, and/or drugs, to stimulate the pharyngeal
muscles. The second strategy, which is less intuitive
but potentially easier to target pharmacologically,
involves reducing the ventilatory requirements of the
patient. It is also worth mentioning that the second
strategy would only be appropriate in patients who can
(at least partially) open their airway during sleep via
reﬂex compensatory mechanisms; otherwise, harmful
levels of hypoventilation may occur. Nevertheless, it is
a potentially viable pharmacotherapy for those patients
that arouse prematurely in response to a ventilatory
stimulus. Moreover, it might be useful as a combina-
tion therapy with the ﬁrst strategy to achieve greater
effects on OSA. For example, the use of an existing or
newly discovered pharmacotherapy or mechanical
device to open the upper airway may prove incom-
pletely effective in some individuals. In such circum-
stances, the addition of a drug that suppresses arousals
or permits lower ventilation during sleep might stabi-
lize breathing and thus eliminate or substantially
reduce OSA.
More research is needed to identify a pharmacother-
apy or combination of pharmacotherapies that can
manipulate the particular phenotypic traits identiﬁed
as signiﬁcant to the pathogenesis of OSA within an
individual patient, and to test the predictive ability of
modelling tools such as the one described above. In
addition, the procedures for identifying the different
OSA phenotypes will need to be made clinically feasi-
ble. To this end, research has begun on techniques for
estimating surrogate measures of the traits from spon-
taneously breathing subjects during clinical sleep
studies.18–21 There may also be other ways to phenotype
OSA using additional measurements. However, those
approaches would most likely require measurements of
‘ventilatory drive’ using an oesophageal catheter or dia-
phragm electromyogram, both of which would be difﬁ-
cult to implement routinely in a clinical setting. Other
potential ways to phenotype (non-invasively) are to try
to ﬁt the ventilation data to a physiological model21 or
perform extra CPAP manoeuvres to measure ‘loop
gain’ or ‘arousal threshold’.11 It is important that these
methodologies be developed in concert with the search
for new rational pharmacological targets for OSA, to
identify who may beneﬁt the most from particular
interventions. This combination of phenotyping and
targeted therapy is the strategy of choice compared
with performing trials that include all patients a subset
of which, a priori, would not be expected to beneﬁt
because the therapeutic target is not relevant to their
OSA phenotype.
STRATEGIC DIRECTIONS FROM THE
PHENOTYPE MODEL AND
IDENTIFYING KEY BARRIERS FOR
OSA PHARMACOTHERAPY
With a view to targeting the critical predisposing factor(s)
for an individual’s OSA pathogenesis, agents that modify
key elements of the ‘phenotype model’ are of the highest
strategic interest. To this end, one of the two major stra-
tegic directions is to decrease Varousal, that is the patient’s
minimum tolerable ventilation during sleep. Given that
Varousal is a composite measure of ventilatory control sen-
sitivity and arousal threshold, a decrease in the former
and/or an increase in the latter would result in a beneﬁ-
cial decrease in Varousal in those individuals in whom this
factor is signiﬁcant to their OSA pathogenesis. Interven-
tions targeting ventilatory control sensitivity and/or arou-
sal threshold, for example, using acetazolamide and
eszopiclone, respectively,23–25 were introduced in the pre-
vious section and are the subject of recent reviews26,27
and other studies (e.g. Refs 28–32). For this reason, this
section will mainly focus on other developments that
identify targets of high interest relevant to the second
major strategic direction in OSA treatment by pharmaco-
therapy. This second strategic direction is to increase
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Figure 3 Predictions can be made about the response to a par-
ticular therapy by simulating treatment on the model diagram
and then calculating the new gap between key parameter
values. In this example, the new gap, which is the difference
between the new Varousal and the new Active V0, is +0.8 L/min
(i.e. a slightly positive value). Therefore, the model predicts that
the patient would likely fail this particular treatment. Active V0,
ventilation off continuous positive airway pressure (CPAP)
(CPAP of 0 cm H2O) when the upper airway muscles are active;
Passive V0, ventilation off CPAP (i.e. at a CPAP of 0 cm H2O)
when the upper airway muscles are passive; Varousal, the ventila-
tion at which arousal occurs, or the ‘minimum tolerable ventila-
tion’; Veupnoea, eupnoeic ventilation on optimum CPAP, which is
a measure of the patient’s ventilatory requirements under rest-
ing conditions when the airway is completely open.
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Active V0 using agents that target an effector that
increases pharyngeal muscle tone and/or reﬂex compen-
satory mechanisms. Here, the aim is to effectively
increase the size and compensatory effectiveness of the
pharyngeal airway in those individuals in whom this fac-
tor is critically signiﬁcant to their OSA pathogenesis.
Importantly, however, there are signiﬁcant physiological
obstacles that are typically overlooked but need to be
explicitly identiﬁed and overcome for any pharmacologi-
cal approach to OSA to be successful. If these impedi-
ments are not overcome, then the likelihood of a
successful pharmacotherapy is low.
In a previous article in Respirology that focused on
controversies and future directions in OSA pathogene-
sis and treatment, the critical barriers that have to be
overcome for any success of a potential OSA pharma-
cotherapy were identiﬁed.33 Here, we update and fur-
ther discuss these barriers, and identify rational
‘druggable’ targets(s) that may be on the horizon to
overcome them. This approach is necessary for this
review because previous attempts at OSA pharmaco-
therapy have largely been ineffective (for reviews, see
Refs 33–38) and in many ways this has been predictable
based on the targets chosen, and because the trials
were comprised of unphenotyped OSA patients, only a
subset of which would be expected to beneﬁt even if
the pharmacological target was rational and effectively
manipulated (discussed in Manipulating the compo-
nents of the phenotype model Section). More recent
clinical studies, however, using agents targeting the sig-
niﬁcant mechanisms of state-dependent pharyngeal
muscle control identiﬁed from basic science
experiments,39–42 have proved beneﬁcial when adminis-
tered to phenotyped patients,43,44 with other studies
ongoing.45–47
The process of identifying an effective OSA pharma-
cotherapy involves satisfying four overarching require-
ments: (i) effectively administering a pharmacotherapy
that (ii) selectively targets the critical mechanisms
involved in an individual’s OSA pathogenesis (iii) at the
required times (i.e. throughout the sleep period) and
(iv) with minimal side effects.33 The latter point is sig-
niﬁcant because the major neurotransmitters involved
in modulating pharyngeal muscle tone across sleep–
wake states40,48 are also involved in sleep–wake regula-
tion and other components of cognition, mood, as well
as brain and autonomic functions (e.g. Ref. 49), such
that some off-target effects are likely.
Once potential therapeutic approaches and targets
have been identiﬁed that can satisfy the above overarch-
ing requirements, there are an additional set of more
speciﬁc obstacles that need to be overcome for an effec-
tive OSA therapy. These obstacles are identiﬁed as:
(i) the delivery problem, deﬁned as the agent effectively
getting to the desired target site(s) to exert its beneﬁcial
effect; (ii) the speciﬁcity problem, deﬁned as the agent
exerting minimal effects at other sites to obscure, or
oppose, the beneﬁcial response; (iii) the pharmacological
problem, identiﬁed as any efﬁcacious response being
obscured by unwanted off-target effects due, for example,
to issues of dose and/or speciﬁcity for the intended ver-
sus unintended receptors/ion channels; (iv) the neurobi-
ology problem, in this case identiﬁed as different
responses to the pharmacotherapy occurring in non-
rapid eye movement (non-REM) versus REM sleep
because of the different brain chemistry comprising these
states; and (v) the variability problem, which has to take
into account that the physical sites of upper airway
obstruction vary within and between patients both across
non-REM and REM sleep, and in the supine and lateral
body positions, such that the pharmacotherapy may be
effective at some times and not others, even in the same
patient.50
Based on the identiﬁcation of the overarching
requirements for an OSA pharmacotherapy, this review
will conclude by discussing potential therapeutic tar-
gets of high interest in the circuitry controlling upper
airway motor output for the purpose of modulating
Active V0.
MAPPING POTENTIAL DRUG
TARGETS IN THE CIRCUITRY
CONTROLLING UPPER AIRWAY
MOTOR OUTPUT
It is not clear whether the difﬁculty in treating OSA
pharmacologically reﬂects a deﬁciency in effective tar-
gets or a deﬁciency in target identiﬁcation. The phar-
macological tractability of a disorder depends on the
differential expression of druggable targets in the
underlying physiological systems that can be modu-
lated for clinical beneﬁt whilst limiting toxicity. There is
now sufﬁcient data to support genome-wide analyses
of the differential expression of druggable targets in the
circuitry controlling motor output to the upper airway
musculature, and this review provides that analysis.
The approach used to identify the candidate
drug targets
For the purposes of this review, we used the differential
search function of the Allen Mouse Brain Atlas’ data-
base of ~25 000 in situ hybridization experiments to
isolate genes that differentiate the hypoglossal motor
nucleus (HMN) and the primary afferents of the HMN
from the rest of the brain.51,52 Separate differential
searches were performed for the HMN and a grouping
of HMN premotor structures (premotor HMN (PRE-
HMN)). A listing of the primary hypoglossal afferents
was taken from previous tracing studies.53,54 These
studies exploit the retrograde transport capabilities of
viral tracers to produce an especially accurate map of
the hypoglossal premotor circuitry. Those studies iden-
tify the primary sources of afferent inputs to the HMN
as the central tegmental ﬁeld, Kölliker-Fuse region,
supra-trigeminal, inter-trigeminal and principal sensory
trigeminal nuclei, nucleus subcoeruleus, parvicellular
reticular formation, dorsal medullary reticular ﬁelds,
Probst’s region and the spinal trigeminal nucleus cau-
dalis (see Appendix S1 (Supplementary Information)
for a list of structural equivalents used in the Allen
Mouse Brain Atlas).52 We created a database of the
genes identiﬁed as having at least a twofold greater
expression in the HMN and/or PRE-HMN relative to
the rest of the brain (Appendix S1 (Supplementary
Information)). The mean fold-change was used in cases
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where multiple in situ hybridization experiments had
been performed for a given gene.
A recent bioinformatics assessment of the ‘druggability’
of the human genome generated a database of all the
protein targets for the drugs approved for clinical use by
the U.S. Food and Drug Administration (FDA).55 Their
analysis conﬁrmed a previously identiﬁed trend56 that
proteins targeted by approved drugs tend to cluster in
four privileged families: G-protein coupled receptors
(GPCRs), ligand-gated ion channels, nuclear receptors
and kinases. Because, for the purposes of this review, we
are interested in potential drug targets capable of modu-
lating cellular activity to increase hypoglossal motor out-
put, we classiﬁed the gene products in our database
according to their status as modulators of neuronal activ-
ity and according to their inclusion in GPCR and ion
channel protein families. These classiﬁcations were made
by screening the differentially expressed mouse genes for
those with human orthologues, followed by cross-
referencing the resulting list with the Gene Ontology Con-
sortium’s database of Molecular Function and Biological
Process annotations of the human genome57,58 (AmiGO
2 version: 2.4.24). Final classiﬁcations were made using
Boolean keyword/phrase searches of the gene ontology
terms assigned to the genes in our database (the list of
the inclusion and exclusion keywords/phrases used are
available in Appendix S1 (Supplementary Information)).
The database was screened for false-positive results by
manually examining the gene ontology terms and in situ
hybridization results for all differentially expressed genes
classiﬁed as GPCRs, ion channels and/or modulators of
neuronal activity. Finally, we cross-referenced our data-
base with the database of protein targets and FDA-
approved drugs55 to match FDA-approved drugs to genes
with enhanced expression in the HMN and/or PRE-
HMN. The list differentially expressed HMN and PRE-
HMN drug targets matched to FDA-approved drugs is
available in Appendix S1 (Supplementary Information).
The identiﬁed candidate drug targets
We identiﬁed 1492 genes from the Allen Mouse Brain
database of in situ hybridization experiments that showed
enhanced expression at the HMN and/or PRE-HMN rela-
tive to the rest of the brain; gene expression in the HMN
was enhanced as high as 33-fold. Of those 1492 genes, the
expression of 1168 are speciﬁcally enhanced in the HMN,
the expression of 88 are speciﬁcally enhanced in the PRE-
HMN and 236 exhibit enhanced expression in both the
HMN and PRE-HMN. A total of 99 genes were classiﬁed
as being probable modulators of neuronal activity, of
which 18 were classiﬁed as GPCRs and 37 were classiﬁed
as ion channels (i.e. part of the privileged protein families
for drug discovery). These 99 targets are listed in Table 1
and are mapped in Figure 4. Protein products of 26/99
genes are targets of 175 FDA-approved drugs. Of those
drugs trialled for the treatment of OSA, a total of 9 act
pharmacologically on 10 of the targets (a list of drugs tri-
alled for the treatment of OSA28,38,44–46 annotated with pro-
tein targets55 is available in Appendix S1 (Supplementary
Information)). Importantly, although the identiﬁed targets,
or combinations thereof, may not ultimately prove effec-
tive for OSA pharmacotherapy, our analysis does reveal
signiﬁcant unexplored potential in terms of trialling
approved drugs and developing new drugs for differen-
tially expressed targets in the circuitry critical for OSA
pathogenesis and that modulate Active V0.
Figure 4 shows that the GPCR group of differentially
expressed genes is associated with the greatest number
of relatively speciﬁc approved drugs (‘speciﬁc’ in this
case refers to drugs having four or less preferred pro-
tein targets). Differentially expressed ion channel genes
are associated with a large number of approved drugs;
however, many of those drugs are non-speciﬁc and
exert their clinical effects by acting on large groups of
similar ion channels (e.g. dalfampridine (4-aminopyri-
dine)47 acts on 40 voltage-gated potassium channel tar-
gets). Moreover, of the top 10 differentially expressed
ion channel genes only 2 are associated with approved
drugs (Table 1). Table 1 also includes the inward-
rectifying potassium 2.4 (Kir2.4) channel (listed as
potassium inwardly rectifying channel, J, 14 on line 20)
that, in the brain, is expressed almost exclusively in the
cranial motor pools that modulate pharyngeal muscle
tone,41,59 although there is also expression in the spinal
cord and in other non-nervous tissue such as kidney
and heart.
Overall, the ion channel class of targets could be a
focus of drug discovery efforts for OSA pharmacother-
apy. However, the lack of speciﬁc ion channel modula-
tors can be taken as an indication of the difﬁculty in
developing speciﬁc drugs within this protein target
class. Nevertheless, the fact that Kir2.4 channels exhibit
markedly lower barium sensitivity compared with other
Kir channels59 indicates that there is something struc-
turally and/or biochemically different about Kir2.4.
This difference may be tractable for medicinal chemists
to develop small molecule inhibitors.
One desired outcome of an OSA pharmacotherapy
would be to sustain pharyngeal muscle activity during
sleep at normal waking levels. If this effect can be
achieved, then the potential of therapeutic efﬁcacy is real-
istic. Manipulation of certain potassium channels at the
hypoglossal motor pool can activate the tongue muscula-
ture throughout sleep to waking levels.40,42 Importantly, it
has been recently shown that introducing a ‘designer’
receptor into the hypoglossal motor pool, and selectively
modulating it with a ‘designer’ drug, led to signiﬁcant and
sustained increases in tongue muscle activity and
increases in upper airway size in preclinical rodent mod-
els.60,61 Moreover, the increases in tongue muscle activity
during sleep persisted for 8–10 h, were of physiological
pattern and magnitude and were speciﬁc and selective for
the tongue with no effects on diaphragm or postural mus-
cle activities or sleep–wake states.60 These results support
targeting a selective and restricted druggable target at the
hypoglossal motor pool to activate tongue motor activity
during sleep. Such candidate targets are present, and can-
didate drugs can also be explored and tested using the
database of resources provided in this review (Table 1,
Fig. 4 and Appendix S1 (Supplementary Information)).
Using this database of candidate drug
targets
There are several factors that ought to be considered
when using this database as a tool for the identiﬁcation
of potential drug targets for OSA. Here, we report
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Table 1 Differential expression of neuronal activity-related genes in the HMN and PRE-HMN regions
ID Gene # Gene name
Fold-change
FDA drugHMN PRE-HMN
GPCRs
1 552 Arginine vasopressin receptor 1A 15.9 — Y
2 257313 Urotensin II domain containing 12.6 — —
3 1269 Cannabinoid receptor 2 6.8 — —
4 7201 Thyrotropin releasing hormone receptor 6.3 — Y
5 6869 Tachykinin receptor 1 5.1 — Y
6 4160 Melanocortin 4 receptor 4.9 — —
7 5726 Taste receptor, type 2, member 138 4.7 — —
8 1395 Corticotropin releasing hormone receptor 2 4.2 — —
9 8325 Frizzled homolog 8 4.2 — —
10 10936 G protein-coupled receptor 75 4.0 2.0 —
11 148 Adrenergic receptor, alpha 1a 3.7 — Y
12 1129 Cholinergic receptor, muscarinic 2, cardiac 3.6 2.4 Y
13 3350 5-Hydroxytryptamine (serotonin) receptor 1A 2.7 — Y
14 3061 Hypocretin (orexin) receptor 1 — 2.5 Y
15 8811 Galanin receptor 2 2.3 — —
16 10866 Neuropeptide FF receptor 2 2.1 — —
17 5745 Parathyroid hormone 1 receptor — 2.0 Y
18 3358 5-Hydroxytryptamine (serotonin) receptor 2C — 2.0 Y
Ion channels
19 116444 Glutamate receptor, ionotropic, NMDA3B 33.4 — Y
20 3770 Potassium inwardly rectifying channel, J, 14 28.0 — —
21 3773 Potassium inwardly rectifying channel, J, 16 16.1 — —
22 51305 Potassium channel, subfamily K, member 9 12.7 — Y
23 1184 Chloride channel 5 9.0 2.4 —
24 53405 Chloride intracellular channel 5 8.5 — —
25 7417 Voltage-dependent anion channel 2 8.0 2.3 —
26 9127 Purinergic receptor P2X, ligand-gated ion channel, 6 6.9 2.2 —
27 59341 Transient receptor potential cation channel, V, 4 6.8 — —
28 54499 Transmembrane and coiled-coil domains 1 6.5 — —
29 93107 Potassium voltage-gated channel, G, 4 5.8 2.1 Y
30 2741 Glycine receptor, alpha 1 subunit 5.7 8.8 Y
31 84230 Leucine-rich repeat-containing 8 family, member C 5.2 — —
32 610 Hyperpolarization-activated, cyclic nucleotide-gated K2 3.7 3.2 Y
33 196527 Anoctamin 6 3.7 — —
34 8514 Potassium voltage-gated channel, shaker-related, β2 3.6 3.2 —
35 441509 Glycine receptor, alpha 4 subunit 3.5 5.6 —
36 309 Annexin A6 3.4 — —
37 3748 Potassium voltage-gated channel, Shaw-related, 3 3.3 2.3 Y
38 9992 Potassium voltage-gated channel, Isk-related, gene 2 3.2 — —
39 55129 Anoctamin 10 3.2 — —
40 5026 Purinergic receptor P2X, ligand-gated ion channel, 5 3.2 2.5 —
41 56666 Pannexin 2 3.0 3.1 —
42 2697 Gap junction protein, alpha 1 2.8 — —
43 59284 Calcium channel, voltage-dependent, gamma subunit 7 2.5 — Y
44 6337 Sodium channel, non-voltage-gated 1 alpha 2.5 — Y
45 348980 Hyperpolarization-activated, cyclic nucleotide-gated K1 2.4 — Y
46 1185 Chloride channel 6 2.4 — —
47 3738 Potassium voltage-gated channel, shaker-related, 3 — 2.3 Y
48 2705 Gap junction protein, beta 1 2.3 — —
49 53822 FXYD domain-containing ion transport regulator 7 2.3 — —
50 7419 Voltage-dependent anion channel 3 2.1 — —
51 6323 Sodium channel, voltage-gated, type I, alpha 2.1 2.2 Y
52 3785 Potassium voltage-gated channel, subfamily Q, 2 2.1 — Y
53 57113 Transient receptor potential cation channel, C, 7 2.0 — —
54 6336 Sodium channel, voltage-gated, type X, alpha 2.0 — Y
55 2743 Glycine receptor, beta subunit — 2.0 —
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differences in RNA expression determined by in situ
hybridization experiments, which are not strictly indic-
ative of differences in protein expression. Secondly, we
did not screen the list of FDA-approved drugs associ-
ated with genes in our database according to the likeli-
hood of their having clinically beneﬁcial effects on
Table 1 Continued
ID Gene # Gene name
Fold-change
FDA drugHMN PRE-HMN
Other
56 201780 Solute carrier family 10, 4 17.0 2.1 —
57 4129 Monoamine oxidase B 11.4 — Y
58 706 Translocator protein 9.3 — —
59 6522 Solute carrier family 4 (anion exchanger), member 2 6.9 2.8 —
60 83697 Solute carrier family 4, sodium bicarbonate cotransporter, 9 6.2 3.9 —
61 1244 ATP-binding cassette, sub-family C (CFTR/MRP), 2 6.1 — —
62 284129 Solute carrier family 26, member 11 6.1 — —
63 147798 Transmembrane channel-like gene family 4 5.8 — —
64 60482 Solute carrier family 5 (choline transporter), 7 5.6 4.1 —
65 55089 Solute carrier family 38, member 4 4.7 — —
66 9628 Regulator of G-protein signalling 6 4.5 — —
67 10057 ATP-binding cassette, sub-family C (CFTR/MRP), 5 4.3 — —
68 80243 PIP3-dependent Rac exchange factor 2 4.2 — —
69 6569 Solute carrier family 34 (sodium phosphate), 1 4.2 2.7 —
70 7421 Vitamin D receptor 4.1 — Y
71 9446 Glutathione S-transferase omega 1 4.0 — —
72 84258 Synaptotagmin III 4.0 2.0 —
73 2745 Glutaredoxin 3.3 — —
74 43 Acetylcholinesterase 3.2 2.3 Y
75 2946 Glutathione S-transferase, mu 7 3.1 — —
76 2273 Four and a half LIM domains 1 3.0 — —
77 11060 WW domain-containing E3 ubiquitin protein ligase 2 2.9 — —
78 6569 Solute carrier family 6 (glycine transporter), 9 2.8 2.2 —
79 392862 Glutamate receptor, ionotropic, δ2-interacting protein 1 2.9 — —
80 89869 Phospholipase C, zeta 1 2.9 — —
81 140679 Solute carrier family 32, (GABA vesicular transporter) member 1 2.8 — —
82 3799 Kinesin family member 5B 2.7 2.7 —
83 6860 Synaptotagmin IV 2.6 — —
84 10518 Calcium and integrin-binding family member 2 2.6 2.0
85 2539 Glucose-6-phosphate dehydrogenase X-linked 2.6 — —
86 128414 Na+/K+ transporting ATPase-interacting 4 2.6 — —
87 7915 Aldehyde dehydrogenase family 5, subfamily A1 2.5 — Y
88 114789 Solute carrier family 25, 25 2.5 — —
89 206358 Solute carrier family 36 (H+/amino acid symporter), 1 2.5 — —
90 1836 Solute carrier family 26 (sulphate transporter), 2 2.3 — —
91 127833 Synaptotagmin II 2.3 2.2 —
92 57084 Solute carrier family 17, 6 2.3 2.9 —
93 285195 Solute carrier family 9 (sodium/hydrogen exchanger), 9 2.3 — —
94 9725 Transmembrane protein 63a — 2.3 —
95 9990 Solute carrier family 12, member 6 2.2 — —
96 84679 Solute carrier family 9 (sodium/hydrogen exchanger), 7 2.2 — —
97 81539 Solute carrier family 38, member 1 2.1 — —
98 23315 Solute carrier family 9 (sodium/hydrogen exchanger), 8 2.1 —
99 54946 Solute carrier family 41, member 3 2.2 — —
A list of genes having at least twofold greater expression in the HMN and/or PRE-HMN relative to the brain-at-large are classiﬁed as
probable modulators of neuronal activity. Numbers under the column identiﬁcation heading ‘ID’ refer to locations of the corresponding
gene information in Figure 1. Gene identiﬁers under column heading ‘Gene #’ refer to the human orthologues of mouse genes. See
Appendix S1 (Supplementary Information) for a listing of the target structures included in the PRE-HMN group as well as contrast
structures used to compute expression fold-changes using the Allen Mouse Brain Atlas differential search function of RNA in situ
hybridization experiments. Under the column heading ‘FDA Drug’, ‘Y’ denotes genes associated with at least one FDA-approved drug.
CFTR/MRP, Cystic ﬁbrosis transmembrane conductance regulator/Multidrug resistance-associated protein; FDA, Food and Drug
Administration; GABA: γ-aminobutyric acid; GPCR, G-protein coupled receptor; HMN, hypoglossal motor nucleus; NMDA3B, N-methyl-
D-aspartate receptor 3B; PIP3, phosphatidylinositol 3,4,5 trisphosphate; PRE-HMN, premotor HMN; —, none.
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hypoglossal motor output. For example, expression of
the alpha 1a adrenergic receptor gene is enhanced at
the HMN, and noradrenergic inputs to the HMN medi-
ate an important component of the state-dependent
modulation of tongue muscle activity.39 We list a total
of 36 FDA-approved drugs capable of targeting this
receptor, 14 of which are antagonists whose direct
effects on the HMN would be expected to negatively
impact upper airway motor tone. Nevertheless, the
number and selectivity of drugs associated with a given
target is useful information, not least because it can be
taken as an indicator of the relative druggability of that
target. Moreover, initial studies have shown that desi-
pramine has beneﬁcial effects on genioglossus muscle
tone, upper airway collapsibility and OSA severity.43,44
Desipramine is a tricyclic antidepressant with strong
noradrenergic and some anti-muscarinic effects. It was
selected for those studies with the aim of preserving
the excitatory noradrenergic tone to the pharyngeal
motor pools that is normally withdrawn in sleep,39,62
and to counter the strong muscarinic cholinergic
receptor-mediated inhibition of the tongue muscula-
ture that occurs in REM sleep.40
This database is also an important resource for
investigators working in preclinical animal models,
because in the case of several targets preclinical studies
will be required to evaluate their potential clinical util-
ity. For instance, expression of the gene for 5-
hydroxytryptamine 2c (5-HT2c) receptors is enhanced
in the PRE-HMN but not in the HMN (Table 1), yet we
do not know what effect the selective agonism of these
receptors would have on hypoglossal motor output, or
Figure 4 A map of potential drug
targets differentially expressed in
the circuitry controlling upper air-
way motor output. This ﬁgure
shows a mapping of the data
listed in Table 1. The numbers
associated with individual bars in
the radial bar chart refer to the
position of the corresponding
gene in Table 1. Genes associated
with the FDA list of approved
drugs are indicated by connec-
tions with bubble graphs. Each
bubble represents a drug or
group of drugs; bubble size is
inversely related to drug speciﬁc-
ity (i.e. the number of protein tar-
gets per drug). The notation in
the bubbles is indicated on the
ﬁgure. Fold-change in gene
expression relative to the whole
brain: , HMN; , group of HMN
primary premotor structures
(PRE-HMN). FDA, Food and Drug
Administration; GPCR, G-protein
coupled receptor; HMN, hypo-
glossal motor nucleus; ISH, in situ
hybridization; PRE-HMN, premo-
tor HMN.
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if 5-HT2c receptor-positive neurons innervate the
HMN. Similarly, the effect of modulating the activity of
urotensin II receptors on hypoglossal motor output has
not been determined but would be worth investigating
given that urotensin II receptor RNA shows a high
degree of differential expression at the HMN (being
12.6-fold higher than for the rest of the brain), and that
urotensin II receptor activation has potent excitatory
effects on central cholinergic neurons.63–65
We recognize that, for the purposes of this review, our
analysis focused speciﬁcally on identifying targets for the
activation of the upper airway musculature. This focus
on the circuitry critical for OSA pathogenesis and the
modulation of Active V0 is, however, only one of the sev-
eral possible pharmacological strategies for the treatment
of OSA. Nevertheless, consulting databases of this kind
will be important regardless of the ultimate stratagem
employed, because when screening candidate drugs for
OSA pharmacotherapy it is prudent to consider the
potential positive or negative effects of drug action on
the targets present in the HMN and PRE-HMN.
FUTURE DIRECTIONS
This review identiﬁes and builds on two major plat-
forms that can be used to support and facilitate future
research. The ﬁrst platform supports the further devel-
opment, reﬁnement, automation and advanced valida-
tion of the phenotyping tools and algorithms used to
identify the principal factors precipitating OSA in indi-
vidual patients. As these approaches mature, the aim
will be to develop practical and cost-effective pheno-
typing tools and devices that are amenable to broad
and routine use by sleep researchers and clinicians.
The second major platform is the resource of candi-
date targets and drugs that was generated for this
review (Table 1, Fig. 4 and Appendix S1
(Supplementary Information)). These resources are
made freely available to explore, select and test such
candidates in preclinical experimental models and
early phase clinical studies. The resources include
identifying differentially expressed genes at critical sites
in the upper airway motor circuitry (HMN and PRE-
HMN), as well as FDA-approved drugs associated with
the differentially expressed genes that are classiﬁed as
probable modulators of neuronal activity, and drugs
that have undergone trials for the treatment of OSA
and their protein targets. It is our hope that this
resource will not only be widely accessed but also
shared to spur new discovery science for OSA patho-
physiology and possible pharmacotherapy. Moreover,
the resource of candidate targets and drugs for the
HMN and PRE-HMN may also be more broadly appli-
cable to other disorders of upper airway motor function
such as motor neuron diseases and dysphagia.
Overall, this review identiﬁes a rational decision-
making strategy with the necessary logical underpin-
nings that any reasonable approach would be expected
to navigate to develop a viable pharmacotherapy for
OSA. It can also be used to identify the critical barriers
that have to be overcome for any success of a potential
OSA pharmacotherapy, and to understand why previ-
ous attempts at OSA pharmacotherapy have largely
been ineffective for predictable reasons. In the Intro-
duction Section of this review, we stated: There is cur-
rently no pharmacotherapy for OSA. However, there is
no principled a priori reason why there shouldn’t be
one—unless the biology simply cannot support it because
of the complexity and individuality of OSA pathogenesis.
The ﬁeld is at the stage now—with the tools, barriers
and candidate targets and drugs identiﬁed—to now
design and perform experiments and clinical trials to
critically test how amenable the upper airway motor
circuitry and OSA may be to pharmacotherapy.
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Appendix S1 This ﬁle contains the database of differentially
expressed hypoglossal motor nucleus (HMN) and premotor
HMN (PRE-HMN) genes, drugs and drug targets. The database is
separated into four parts on separate spreadsheets:
(i) differentially expressed HMN genes; (ii) differentially
expressed PRE-HMN genes; (iii) Food and Drug Administration
(FDA)-approved drugs associated with differentially expressed
HMN and PRE-HMN genes classiﬁed as probable modulators of
neuronal activity; and (iv) drugs that have undergone trials for
the treatment of obstructive sleep apnoea and their protein tar-
gets. Gene expression data were obtained from the Allen Mouse
Brain Atlas database of in situ hybridization experiments.51,52
Parts (i) and (ii) include a listing of the target and contrast struc-
tures used for the differential searches. Biological process and
molecular function gene annotations are from the Gene Ontol-
ogy Consortium’s AmiGO 2 database57,58 (AmiGO 2 version:
2.4.24). Protein target annotations of FDA-approved drugs are
from the Santos et al.’s database.55
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